TempraMed's VIVI Cap 1 is changing the way people who inject insulin live their lives

 

VIVI Cap 1 is the world's first and only reusable insulin pen cap temperature shield that always keeps in-use insulin at the right temperature

 
[16-July-2021]
 
 

TEL AVIV, Israel, July 16, 2021 /PRNewswire/ -- TempraMed is creating easy to use, hassle free solutions that save patients lives by protecting them from damaged medications. TempraMed's products provide the last mile control management for injectable and temperature sensitive pharmaceuticals, helping patients to manage and control their medications, enabling them to live safer and more spontaneous lives.

Watch the video: https://www.youtube.com/watch?v=PF6bN57BWaw

TempraMed's recently launched VIVI Cap 1 is an easy-to-use reusable insulin pen cap that keeps diabetes insulin at a safe temperature 24/7 365 days a year, for years on end without need for any user intervention. The product is FDA registered and CE marked.

Insulin is a protein that spoils and degrades in the wrong temperature conditions. From the point of manufacturing up until it is used, insulin needs to be kept between 36° to 46°F. During use, insulin does not have to be refrigerated but it should stay below 86°F and should not freeze. Insulin must be protected from such exposure.

Injecting insulin that has broken down due to time or temperature, results in poor blood sugar control, and in time can lead to increased dosages and sometimes hospitalization for stabilization.

The VIVI Cap 1 shields insulin in-use from potential temperature damage. Thus, reducing the risk of using damaged insulin and wasting money from discarded insulin that might have been compromised.

Mr. Ron Nagar, TempraMed CEO and Founder, stated "After spending years recognizing the endless struggle that people with diabetes have to gain control over blood glucose levels, I noticed that those on insulin, take it for granted that insulin is always the same and at its best. But sadly, that is not the reality, so in order to protect the insulin without adding any hassle we developed this unique device and made it available for all."

VIVI Cap uses a unique patented combination of special insulation with "self-regenerating" heat absorbing material and control electronics, this enables the device to operate for years without requiring any user attention or handling. There are no power requirements, no charging and no preliminary preparations needed. For people spending their working days outdoors, there has not been an alternative hassle-free solution that can be used every day to protect insulin from spoiling.

About TempraMed

TempraMed develops, manufactures and markets; validated, compact & maintenance free smart personal storage solutions for injectable medications. By bringing to the market temperature regulating technology developed for space, TempraMed is filling an unmet need for people who inject medications and would like to live their lives spontaneously and with less hassles. TempraMed is led by a world class team of experts in the field of medical and diabetes; Ilan Cohen TempraMed's chairman has been one of Israel's leading visionaries since 1985. He is the former Director General of the Israeli Prime Minister's office, Co-Founder of POC Management Consulting, and director and partner of a multitude of top Israeli companies and organizations including high technology. Roger O. Goldman; Board Member is the former chair of the JDRF and is a sought-after strategic, charismatic, and visionary leader and advisor with a proven track record of transforming mindsets and building success at all levels of an organization. Ron Nagar, Founder and CEO is a medical device serial entrepreneur and inventor, he is the Co-Founder of InsuLine Medical and Glucon.

Contact:
Brenda Zeitlin
TempraMed
+1 (800) 871-9923
brenda@tempramed.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/temprameds-vivi-cap-1-is-changing-the-way-people-who-inject-insulin-live-their-lives-301335496.html

SOURCE TempraMed

 

Back to news